BIGBEAR
PHARMACEUTICAL
Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
AuthenticGuaranteeFast DeliveryPrivacy Idhifa (Ensidipin), an oral formulation jointly developed by Celgene and Agios Pharmaceuticals, is indicated for adult patients with relapsed or refra···【More】
Update: 24 Mar,2026Source: BigbearViews: 106
On August 1, 2017, the U.S. Food and Drug Administration (FDA) officially approved IDHIFA (enasidenib) for the treatment of adult patients with relaps···【More】
Update: 24 Mar,2026Source: BigbearViews: 108
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
